Media stories about Heat Biologics (NASDAQ:HTBX) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Heat Biologics earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.3659950062406 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, Griffin Securities began coverage on shares of Heat Biologics in a report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price target on the stock.

Heat Biologics (NASDAQ HTBX) remained flat at $$0.37 during trading hours on Wednesday. 428,600 shares of the company’s stock were exchanged, compared to its average volume of 607,971. Heat Biologics has a 1 year low of $0.30 and a 1 year high of $1.25.

Heat Biologics (NASDAQ:HTBX) last posted its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Heat Biologics had a negative net margin of 1,184.92% and a negative return on equity of 149.69%. The business had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.50 million. equities research analysts expect that Heat Biologics will post -0.38 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Heat Biologics (HTBX) Share Price” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/20/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-heat-biologics-htbx-share-price.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Insider Buying and Selling by Quarter for Heat Biologics (NASDAQ:HTBX)

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.